Top brand choice
Strength | Pack Size | Qty | |
---|---|---|---|
Strength
400mg
|
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Viramune XR is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and children aged 6 years and older. It works by binding directly to HIV-1 reverse transcriptase, blocking RNA- and DNA-dependent DNA polymerase activities and thereby inhibiting viral replication. Viramune XR is the extended-release formulation of nevirapine, allowing for once-daily dosing and improved patient adherence in chronic HIV therapy.
Fact Table | |
Formula | C15H14N4O |
License | US FDA |
Bioavailability | >90% (oral) |
Legal status | Rx-only |
Chemical Name | 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one |
Elimination half-life | 25–30 hours (extended-release) |
Dosage (Strength) | Viramune XR: 100 mg, 400 mg extended-release tablets |
Pregnancy | Use only if clearly needed (Category B) |
Brands | Viramune, Viramune XR |
Protein binding | 60% |
PubChem CID | 4463 |
MedlinePlus | a601002 |
ChEBI | CHEBI:7504 |
ATC code | J05AG01 |
DrugBank | DB00238 |
KEGG | D00434 |
Routes of administration | Oral |
Viramune XR should be initiated in patients who have already completed a 14-day lead-in period with immediate-release Viramune (nevirapine IR 200 mg once daily) to reduce the risk of rash.
Take with or without food, but do not crush or chew the extended-release tablets. Swallow whole. Dose adjustments may be needed for hepatic impairment or in combination with other CYP3A-modulating drugs.
Each extended-release tablet contains:
Inactive ingredients may include:
Viramune XR is contraindicated in patients with:
Boxed Warning: Serious and potentially fatal hepatotoxicity and severe skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have occurred. Monitor liver function tests (AST, ALT) frequently during the first 18 weeks of therapy, then periodically thereafter. Discontinue permanently if severe rash or liver abnormalities develop. Use caution in patients with underlying hepatic disease, chronic hepatitis B or C, or those on hepatotoxic drugs. Avoid initiating in women with high CD4+ counts unless benefits outweigh risks.
Common and potential side effects include: